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Summary⋅ 
 
Among the four traditional causes of arterial hypoxemia (table 1) and 
hypercapnia (alveolar hypoventilation and VA/Q heterogeneity) VA/Q 
inequality is the most important mechanism of respiratory gas exchange 
impairment. In the mild 1970s a new technique has been developed able to 
study ventilation-perfusion ratios distributions named “multiple inert gases 
elimination technique”, MIGET. 
The technique is based on the quantitative relation of the blood-gas partition 
coefficient (λ) of a gas - the VA/Q ratio - and the capacity of an alveolar unit to 
exchange that gas (Fahri, 1967). By using 6 different inert gases in trace 
concentrations, covering a wide spectrum of partition coefficients from 0.005 
(SF6) to 300 (acetone), it is possible to characterize the distribution of the 
VA/Q ratios within the whole lung. By using a lung model of 50 compartments, 
retentions and excretions of six gases give an estimation of a continuous 
distribution of the pulmonary blood flow and alveolar ventilation, respectively, 
against VA/Q ratios on a logarithmic scale. 
A complete VA/Q study also analyses extra pulmonary factors determining 
gas exchange as cardiac output, total ventilation, oxygen consumption, FIO2, 
type and concentration of Hb, pH and body temperature.  
The two major advantages of this technique are: 
• It gives an estimation of alveolar ventilation and pulmonary blood flow 
without disturbing either vascular or bronchomotor tone; 
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• It facilitates the understanding of the complex interplay of intra and 
extra pulmonary factors determining pulmonary gas exchange. ⋅ 
MIGET has been used to study the mechanisms of gas exchange impairment 
in main respiratory diseases, their eventual relationships with structural 
alterations, the effects of O2 breathing and the effects of some of the drugs 
commonly used. 
The first studies conducted between 70s and 80s on asthmatic patients 
described a variable degree of VA/Q inequalities (increased blood flow 
dispersion) beside a normal or mildly reduced PaO2.  
Patients with stable chronic severe asthma showed modest VA/Q 
abnormalities maintaining a near normal PaO2, despite a severe degree of 
airway obstruction, likely because of less inflammatory changes at a 
peripheral level or because of a more active hypoxic pulmonary 
vasoconstriction. These data contrast with those of COPD patients showing, 
for a similar degree of bronchoconstriction, much greater VA/Q inequalities.  
In acute severe asthma gross VA/Q abnormalities were observed, 
proportionally with asthma attack severity, with predominant bimodal blood 
flow distribution and a variable amount of cardiac output to areas with low 
VA/Q ratios. 
No correlation has been found between respiratory and inert gases exchange 
and airways bronchoconstriction indices. This finding suggests that 
spirometric abnormalities reflect predominantly bronchoconstriction in larger 
and medium sized airways, while gas exchange and VA/Q abnormalities 
reflect more peripheral airways impairment. 
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In COPD patterns and severity of VA/Q inequalities differ among patients and 
change with the evolution of the disease and with the clinical state of the 
patient. ⋅ 
In all cases VA/Q inequalities appear to be the main cause of hypoxemia but 
no O2 diffusion limitation or true shunt have never been detected. 
No correlation has been found between severity of airflow obstruction and 
VA/Q inequalities as patients with mild to moderate COPD already show 
notable VA/Q mismatch. However the degree of VA/Q dispersion is usually 
higher in more severe patients. 
Barberà and coworkers studied the mechanisms of gas exchange impairment 
during COPD exacerbation. They observed increases in Log SDQ, low VA/Q 
ratio units, cardiac output and oxygen consumption. By using MIGET 
algorithm, they definitely demonstrated that gas exchange worsening during 
exacerbations is essentially due to VA/Q mismatching and amplified by the 
decreased mixed venous PO2, resulting from a greater VO2. 
The effects of bronchodilators in COPD have also been investigated since 
the beginning of 80s: an unexpected worsening of basal degree of VA/Q 
mismatching was observed after β2-agonists, likely as effect of hypoxic 
vasoconstriction release. 
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“Adenosine 5’-monophosphate (AMP) challenge in mild asthma: 
cellular and gas exchange responses” ⋅ 
Abstract 
BACKGROUND: It has been suggested in asthma that bronchial challenge to 
indirect agents, such as 5’-adenosine monophosphate (AMP), offers a better 
estimate of airway inflammation than direct agents. We explored the effects 
of AMP challenge on lung function, including ventilation-perfusion (VA/Q) 
relationships as a marker of peripheral airway inflammation, and induced 
sputum, and compared with methacholine (MCh) bronchoprovocation. 
METHODS: A randomized, single-blinded, cross-over study using dose-
response curves was designed, one week apart. Twelve non-smoking mild 
asthmatics (age, 25±(SE)1 yr; FEV1, 92±4% predicted) were studied at 
baseline and 5, 15 and 45 min after equivalent target responses to provoke a 
30% fall in FEV1 (AMP, by 35±2%; MCh, by 37±2%). Sputum was collected 
before and 4 h after each challenge. RESULTS: Five min after challenge, 
PaO2 fell (AMP, by 4.1±0.4 kPa; MCh, by 4.3±0.4 kPa) due to VA/Q 
mismatching as assessed by an increased overall index of VA/Q 
heterogeneity (DISP R-E*; normal values, <3.0) (AMP, by 3.8±0.7; MCh, by 
4.6±0.7), without differences between agents. Compared with MCh, there 
were increases in cardiac output (by 20±8%) and oxygen consumption (by 
10±4%)
 
(p<0.05 each) after AMP possibly related to an inotropic effect. Four 
h after challenge, sputum neutrophils increased after AMP (from 48±7% to 
62±6%, p<0.05) without associated changes in eosinophils. The number of 
neutrophils in the baseline sputum showed a significant correlation with the 
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concentration of IL-8 in the supernatant (r, 0.767; p<0.01) and with the 
increases in respiratory system resistances (Rrs; r, 0.803; p<0.01) and 
alveolar-arterial PO2 difference (AaPO2; r, 0.657; p<0.05) after AMP 
challenge. CONCLUSIONS: AMP challenge provoked an intense 
bronchoconstriction of similar magnitude to that of gas exchange 
abnormalities along with a neutrophilic response. MCh caused similar lung 
function changes without any sputum cellular effect. ⋅ 
 
“Effects of nebulized salbutamol on pulmonary gas exchange during 
COPD exacerbations and in stable conditions”. 
Abstract 
Short-acting β2-agonists are commonly used in COPD, although their effects 
on pulmonary gas exchange are not fully understood.  
We investigated the effects of nebulized salbutamol (5 mg) on ventilation-
perfusion (VA/Q) inequalities in COPD patients during exacerbations (phase 
E) and in stable clinical condition (phase S). We studied 20 patients (1F:19M; 
5 smokers, 15 ex-smokers; 67±2[SEM] yrs; FEV1, 37±4% pred.) before and 
at 30 and 90 min after salbutamol. Nine patients completed both phases E 
and S (seven with VA/Q measurements in both phases), 11 only phase E.  
In phase E salbutamol significantly improved FEV1 and inspiratory capacity 
(by 14±3% and 10±3%; p<0.01), increased cardiac output (QT, by 13±3%, 
p<0.01) and decreased mean arterial pressure (MAP; by 8±2%, p<0.01), 
while PaO2 showed a mild, not significant, decrease only at 30 min (PaO2 
from 61.1±2.0 to 59.1±2.0) due to a mild increase in the dispersion of 
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pulmonary blood flow (Log SDQ; from 1.17±0.07 to 1.23±0.06, p<0.01). 
Patients of phase S, in comparison with phase E (paired analysis), showed a 
similar spirometric response to salbutamol but more marked and prolonged 
negative effects on gas exchange, as PaO2 passed from 70.7±4.4 to 
63.6±3.5 (30 min) and to 64.5±3.2 mmHg (90 min) and LOG SDQ passed 
from 0.96±0.09 to 1.12±0.13 and to 1.15±0.13 (two-ways ANOVA, p<0.01; 
p<0.02). QT and MAP responses to salbutamol in phase S did not 
significantly differ from phase E. ⋅ 
The bronchodilator effect of salbutamol in COPD is associated with 
worsening of gas exchange and VA/Q mismatching due to pulmonary 
vasodilatation. This effect is more evident in stable condition as pulmonary 
vasculature tone is more relaxed and liable to vasodilatation than during 
exacerbations (hypoxic pulmonary vasoconstriction). 
 
In conclusion, the first study on AMP and MCh challenges in asthma was 
aimed at the investigation on the old hypothesis of dissociation between large 
and medium sized airways, accounting for the obstructive spirometric 
abnormalities of asthma, and small airways, where inflammatory and 
remodelling processes can affect gas exchange efficacy (PaO2, AaPO2, VA/Q 
balance) independently by the bronchomotor tone. Unfortunately we could 
not find any differences in terms of VA/Q imbalance between two challenges, 
as probably the impact of such an intense bronchoconstriction (PD30) is too 
high to let visible gas exchange differences specifically related to peripheral 
airways involvement. However the neutrofilic response we observed after 
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AMP is a confirmation that this model of airways challenge is more 
representative of natural broncho-constrictive and inflammatory processes of 
real asthma attacks. ⋅ 
By continuing on this line of investigation on small airways we intend to 
integrate the information deriving from MIGET with old and newer other 
techniques (closing volume, exhaled NO, ventilatory scan, etc.) looking for 
parameters providing some functional and morphological information on 
pathological processes of small airways. We aim to evaluate the presence of 
VA/Q and gas exchange abnormalities, which remain commonly unidentified, 
beside mild spirometric abnormalities and to correlate them with the other 
parameters considered, hoping to achieve a new definition of small airways 
diseases in asthma. 
 
The second work focuses on COPD by comparing the effects of inhaled 
salbutamol on gas exchange during exacerbations and under stable 
conditions.  
In particular, this clinical research experience has provided a better 
knowledge of β2-agonists vasoactive and inotropic effects, potentially 
influencing the general hemodynamic balance, and has underlined, therefore, 
the complexity of the interaction among intra pulmonary and extra pulmonary 
factors determining pulmonary gas exchange in COPD. 
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Introduction⋅ 
 
Principles of physiology and assumptions. 
The principal function of the lungs is to provide oxygen uptake (VO2) and 
carbon dioxide elimination (VCO2) adequate to satisfy the whole body 
metabolic request. Pulmonary gas exchange requires adequate levels of 
ventilation and perfusion in the alveoli. The old compartmental model of Fenn 
et al. and Riley and Cournard describes three ideal lung zones of ventilation-
perfusion matching: 1. the ideal lung, where ventilation and blood flow are 
appropriately apportioned; 2. the shunt fraction, in which perfusion reaches 
unventilated areas; the physiological dead space, where the compartment is 
ventilated but not perfused [1-2]. Unfortunately, this historical model is not 
sufficient to explain VA/Q relations inequalities that have been demonstrated 
to be the main cause of gas exchange abnormalities. Among the four 
traditional causes of arterial hypoxemia (table 1) and hypercapnia (alveolar 
hypoventilation and VA/Q heterogeneity) VA/Q inequality is the most important 
mechanism of respiratory gas exchange impairment [3-5]. 
Table 1. Factors determining arterial hypoxemia. 
                    Intrapulmonary               Extrapulmonary 
                                                                              Main factors  
• Alveolar hypoventilation • ↓Minute Ventilation 
• VA/Q mismatching • ↓Cardiac Output 
• Shunt • ↓Inspired PO2 
• Alveolar-end capillary O2 diffusion limitation • ↑O2 uptake 
  
                                                                      Secondary factors  
 • ↓P50 
 • ↓ [Hb] 
  • ↑pH 
P50= PO2 that corresponds to 50% oxyhaemoglobin saturation 
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Consequently, the most complete approach to investigate the 
pathophysiology of gas exchange impairment in respiratory diseases is the 
study of VA/Q inequality. ⋅  
In the mild 1970s a new technique has been developed able to study 
ventilation-perfusion ratios distributions named “multiple inert gases 
elimination technique”, MIGET. 
This technique is based on the historical work of Fahri of the mid 1960s that 
demonstrated the quantitative relation of the blood-gas partition coefficient 
(λ) of a gas - the VA/Q ratio - and the capacity of an alveolar unit to exchange 
that gas [6]. 
The basic equation for a single lung unit gas exchange was established: 
PcPA=Pv·λ/(λ+VA/Q)     Equation 1 
This equation expresses mass balance during steady state elimination of the 
inert gas (gas not participating in metabolic processes) and indicates that 
both end capillary (Pc) and alveolar (PA) partial pressures of an inert gas 
(assumed to be equal in a single lung unit) depend on the
 
partial pressure of 
this gas in the venous side of the capillary
 
(Pv) and on the solubility of that 
gas, expressed as partition coefficient (λ) and the VA/Q ratio of the lung unit. 
As Pc/Pv and PA/Pv represent retention in the blood and excretion of the gas, 
respectively, the above equation can also be expressed as following: 
R = E = λ/(λ+VA/Q).    Equation 2 
The retention and excretion of an inert gas depend on its partition coefficient 
and on VA/Q ratio of that unit. By using 6 different inert gases in trace 
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concentrations, covering a wide spectrum of partition coefficients from 0.005 
(SF6) to 300 (acetone), it is possible to characterize the distribution of the 
VA/Q ratios within the whole lung within the widest possible range (from 0.05 
to 100). The six gases generally used, in increasing order of λ, are: SF6, 
ethane, cyclopropane, enflurane or halothane, diethilether and acetone. By 
using a lung model of 50 compartments, the retentions of six gases give an 
estimation of a continuous distribution of the pulmonary blood flow against 
VA/Q ratios on a logarithmic scale (fig 1). Analogously, the excretions of six 
inert gases provide an estimation of the distribution of the alveolar ventilation 
against VA/Q ratios. ⋅ 
This technique, applicable both in health and disease, despite the classical 
division of lung in three functional department [1-2] permits to separate areas 
with low but finite VA/Q ratios (VA/Q ratio<0.1) from areas whose VA/Q ratios 
is zero (shunt), and regions with high VA/Q ratios (VA/Q ratio>10) from 
regions that are unperfused (dead space). After reaching a steady state, the 
concentrations of each gas are measured in the mixed arterial blood and 
mixed expiratory gas. The curve relating arterial concentration and solubility 
is transformed into a virtually continuous distribution of blood flow against 
VA/Q, using techniques of numerical analysis. The relation of between 
expired concentration and solubility is similarly converted into the distribution 
of ventilation. 
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Some important assumptions are at the base of MIGET: ⋅ 
a. The existence of steady state conditions in all VA/Q units that means 
the constancy of excretion and retention during the whole period of 
measurements. 
b. Diffusion equilibration between alveolar gas and end capillary blood 
for each gas. 
c. A lung model consisting in a number of homogenous compartments in 
parallel, each with constant and continuous ventilation and perfusion. 
d. All diffusive processes affecting pulmonary gas movements are 
sufficiently rapid not to affect gas exchange. 
MIGET is able to provide then, a quantitative picture of lung units with 
particular VA/Q ratios in a good graphical representation and computes the 
amount of blood flow and ventilation associated with these lung units (Figure 
1). This image is useful in giving an overview of the distributions and 
suggesting patterns of distribution as unimodal (normal or broad), bimodal or 
trimodal. 
 
The quantification of VA/Q inequalities is better expressed through some 
numerical indices: 
• Mean V, Mean Q, mean values of VA/Q ratios of ventilation and 
perfusion curves. 
• Log SDV, Log SDQ, the standard deviation of mean values in a 
logarithmic scale. 
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• Low VA/Q, the percentage of blood flow in units whose VA/Q ratio is 
lower than 0.01. ⋅ 
• High VA/Q, the percentage of blood flow in units whose VA/Q ratio is 
greater than 10. 
• Shunt, blood flow percentage to lung units with VA/Q ratio<0.05. No 
post-pulmonary shunt is detectable by MIGET. 
• Dead space, ventilation in units of VA/Q ratio>100.  
• DISP R-E*, the root mean square value of retention minus excretion, an 
overall index of VA/Q heterogeneity. 
As the MIGET algorithm does not consider diffusion limitations, the expected 
value of PaO2 through this mathematical model does not always correspond 
to the real PaO2 measured in the blood; the positive difference between 
expected and measured PaO2 can likely be ascribed to an oxygen diffusion 
limitation. 
Since the first works made in the 70s on the mathematical analysis of O2 and 
CO2 behaviour in blood, it was clear that variables derived from physiological 
gases (PaO2, PaCO2, alveolar-arterial PO2 difference [AaPO2], venous 
admixture and physiological dead space) vary with VA/Q matching, but also 
with changes in minute ventilation, cardiac output, inspired PO2,etc. (table 1) 
[7]. 
A complete VA/Q study also analyses extra pulmonary factors determining 
gas exchange as cardiac output, that can directly be measured (if inert 
gases levels are known in mixed venous blood, arterial blood and mixed 
expired gas) or using indocyanine green, total ventilation (VE), oxygen 
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consumption (VO2), FIO2, type and concentration of Hb, pH and body 
temperature. MIGET permits to estimate the influence of each of extra 
pulmonary factors by introducing the observed values (singly or in any 
combination) of each factor in the algorithm that calculates VA/Q inequality 
and the expected PaO2. ⋅ 
This estimation is useful to understand the qualitative and quantitative role 
of each intra pulmonary and extra pulmonary factors in determining gas 
exchange. 
The two major advantages of this technique are: 
• It gives an estimation of alveolar ventilation and pulmonary blood flow 
without disturbing either vascular or bronchomotor tone; 
• It facilitates the understanding of the complex interplay of intra and 
extra pulmonary factors determining pulmonary gas exchange. 
 
Practical aspects 
Originally the technique was performed using inert gases levels determined 
from three different sites: mixed venous blood, arterial blood and mixed 
expiratory gas. The modality permits a direct measurement of all variables of 
equation 2 and a direct calculation of cardiac output.  It implies the placement 
of a catheter in the pulmonary artery.  
The version of MIGET most commonly used only requires mixed expiratory 
and peripheral venous sampling. In this case cardiac output is measured by 
indocyanine green (dye dilution) (Figure 2).  
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To inscribe the dye curve, 5 mg of dye in 1 ml of water are rapidly flushed 
into the venous catheter and arterial blood is withdrawn at a constant rate of 
20 ml·min-1. Adequate curves are obtained prior to recirculation for the 
conventional Stewart-Hamilton analysis with a cardiac output computer (DC-
410 Waters Instruments Inc. Rochester, MN). ⋅ 
The following equation is at the base of cardiac output measurement: 
QT·λ·Pv=QT·λ·Pa+VE·PE      Equation 3 
Where PE is mixed expiratory gas and Pv can be computed from mass 
balance: 
Pv= Pa + (VE ·PE/λ·QT).      Equation 4 
Finally, a third modality of MIGET requiring only mixed expiratory and 
peripheral venous sampling is also available. This is obtained from a distally 
oriented canula inserted into a peripheral vein (usually in the forearm 
opposite to the side of the infusion of the inert gas solution). As inert gases 
are not metabolized by tissues after 90 min of infusion in a resting position 
virtual equilibration between blood and tissues is achieved and the peripheral 
venous blood reflects the inert gas concentration of the inflowing arterial 
blood. 
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Instrumentation 
Some fundamental instruments are necessary in MIGET: 
 Exhaled air mixing box (heated), for the mixed expiratory gas 
sampling: an adapted circuit takes the expired air to a mixing box (10 
L)  that is heated at a temperature of about 40-45 °C , in order to avoid 
inert gases deposition on tube internal walls. Mixed expiratory 
samples are collected from the mixing box to measure inert and 
respiratory gases. ⋅ 
 Respirometer, Ventilatory recordings (minute ventilation, respiratory 
rate, tidal volume) are taken during the study. A  Wright respirometer 
is commonly used. 
 Inert and respiratory gases analyser. Inert gases detection is 
commonly made by a chromatograph accurately set-up to describe all 
gases peaks. Chromatograph is provided with a flame ionisation 
detector (FID) able to measure all gases excluding SF6 that are 
hydrocarbons and with an electron capture detector (ECD) to measure 
SF6 [8-9].  
 A cardiac output computer, if a pulmonary catheterisation is not 
performed. 
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MIGET in healthy subjects 
The typical VA/Q distribution of normal subjects aged less than 30 years at 
rest, breathing room air, is characterised by narrow perfusion and ventilation 
curves centred around 1 VA/Q ratio in the abscissa (figure 1).  
Mean values of the second moment of the distribution (Log SDQ and Log 
SDV) range from 0.35 to 0.43 [10]. The upper 95% confidence limit for Log 
SDQ is 0.60 and for Log SDV is 0.65 [11-14]. 
No perfusion in lung units with VA/Q ratios <0.005 (shunt) is present [15]. The 
amount of ventilation to lung units with VA/Q ratios >100 (dead space) is 
approximately 30%, including anatomical, physiological and instrumental 
dead space. ⋅ 
Neither perfusion to lung units with VA/Q ratio <0.10 (low VA/Q) is observed, 
nor ventilation to lung units with VA/Q ratio>10 (high VA/Q). 
Cardus et al. investigated changes of VA/Q inequality in healthy subjects with 
aging [16]. By studying 64 individuals aged between 18 to 71 years they 
observed only a slight increase in Log SDQ and Log SDV in parallel with 
PaO2 mild decrease (by 6 mmHg). The upper 95% confidence limits in 
subjects aged 70 yrs were 0.70 for Log SDQ and 0.75 for Log SDV. They 
demonstrated that the observed decrease in arterial oxygenation (increased 
alveolar-arterial O2 gradient, AaPO2) with age is due to VA/Q inequality.  
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MIGET in respiratory diseases 
In the last three decades enormous progress has been made in the study of 
pathophysiology of acute and chronic respiratory diseases with the 
contribution of MIGET. 
After a wide investigation on MIGET in normal subjects under different 
conditions of exercise, altitude, O2 inspiratory fractions (FIO2) and age [10-
16], MIGET has been used to study the mechanisms of gas exchange 
impairment in main respiratory diseases, their eventual relationships with 
structural alterations, the effects of O2 breathing and the effects of some of 
the drugs commonly used [17-18]. 
The milestone in the literature on the contribution of MGET to pulmonary 
medicine is the series published on Thorax between 1994 and 1995 
composed of six articles [19-24]. ⋅ 
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Bronchial asthma⋅ 
The first description of gas exchange impairment (mild to moderate 
hypoxemia) in asthmatic patients belongs to two Australian chest physicians 
in the 1967 [25]. McFadden et al confirmed the presence of hypoxemia and, 
in more severe cases, of hypercapnia in 101 patients suffering an acute 
exacerbation of asthma [26]. They postulated that obstructive changes in 
peripheral airways could explain the refractoriness to standard 
bronchodilators and relapses. Since MIGET was introduced in respiratory 
medicine in the 70s, a big amount of information has been collected on the 
mechanisms of gas exchange impairment in the different clinical forms of 
asthma. 
The first study of Wagner on asymptomatic asthmatics in the 1978 showed 
that beside normal values of PaO2 (all but one patient had normal or slightly 
reduced PaO2) a bimodal blood flow distribution (increased Log SDQ) was 
described, with areas with low VA/Q ratio [27]. Subsequent studies showed 
lower prevalence of VA/Q inequalities, probably as a consequence of 
differences in patient selection, clinical management and treatment [28-31]. 
 In patients with stable chronic severe asthma the VA/Q abnormalities were 
quite modest (broad unimodal distribution, mildly increased Log SDQ and 
Log SDV) [32-33]. Likely, these patients maintain a near normal PaO2 
despite a severe degree of airway obstruction because of less inflammatory 
changes at a peripheral level or because of a more active hypoxic pulmonary 
vasoconstriction. This findings contrast with those of COPD patients that, 
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with a similar degree of bronchoconstriction, show much greater VA/Q 
inequalities and gas exchange impairment. ⋅ 
In acute severe asthma gross VA/Q abnormalities were observed, 
proportionally with asthma attack severity, with predominant bimodal blood 
flow distribution and a variable amount of cardiac output to areas with low 
VA/Q ratios [34-36]. Neither dead space nor high VA/Q ratios were described. 
The increased concentration of inspired O2 and the administration of 
bronchodilators appeared to enhance the perfusion of low VA/Q ratios. 
All these studies have led to some general conclusions: 
• Usually PaO2 is relatively preserved; this data could be explained with 
the contribution of increased ventilation and cardiac output (extra 
pulmonary factors); 
• No correlation has been found between respiratory and inert gases 
exchange and airways bronchoconstriction indices [37-38]. This 
suggests that spirometric abnormalities reflect predominantly 
bronchoconstriction in larger and medium sized airways, while gas 
exchange and VA/Q abnormalities reflect more peripheral airways 
impairment. 
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COPD ⋅ 
Chronic obstructive pulmonary diseases are characterised by a wide 
spectrum of gas exchange abnormalities, ranging from mild hypoxemia to 
severe respiratory failure requiring ventilatory support. In all cases VA/Q 
inequalities appear to be the main cause of hypoxemia [39]. By converse, no 
O2 diffusion limitation or true shunt have been demonstrated in COPD 
patients. 
The patterns and the severity of VA/Q inequalities differ among COPD 
patients and change with the evolution of the disease and with the clinical 
state of the patient. 
An historical work of Wagner and coworkers described tow different patterns 
of VA/Q mismatch in a group of severe COPD patients [39]. Some patients 
showed an increased number of high VA/Q ratio units (high pattern); other 
patients showed numerous areas with low VA/Q ratios (low pattern) (Figure 
3). While the high pattern was more frequent among emphysematous 
patients, no other consistent association between VA/Q pattern and clinical 
pictures was found. 
Other studies followed this one but no correlation was found between 
severity of airflow obstruction and VA/Q inequalities as patients with mild to 
moderate COPD already showed notable VA/Q mismatch [40-41]. However 
the degree of VA/Q dispersion of these patients was lower than in more 
severe patients. 
During exacerbations it has been observed worsening of VA/Q distributions 
that are probably related to reversible functional abnormalities (mucus 
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impaction, bronchospasm, bronchial wall oedema) [42-43]. Barberà and 
coworkers studied the mechanisms of gas exchange impairment during 
COPD exacerbation [43]. Thirteen patients were studied during 
hospitalization and approximately 5 weeks after discharge. During 
exacerbations they observed increases in Log SDQ, due to a greater 
perfusion of low VA/Q ratio units, in cardiac output and oxygen consumption 
(VO2). By analysing the specific effect of each intra and extra pulmonary 
factor determining arterial oxygenation through MIGET logarithm it was 
demonstrated that gas exchange worsening during exacerbations is 
essentially due to VA/Q mismatching and amplified by the decreased mixed 
venous PO2, resulting from a greater VO2. ⋅ 
The effects of bronchodilators in COPD have been investigated since the 
beginning of 80s, as they have known spirometric and clinical effects but not 
so clear effects on gas exchange. The bronchodilation induced by these 
drugs was unexpectedly accompanied by a worsening of basal degree of 
VA/Q mismatching, likely as effect of a possible interaction with the 
mechanism of hypoxic vasoconstriction [44-46]. This hypothesis is sustained 
by the work of Melot and coworkers that described a fall in pulmonary 
vascular resistance and PaO2 after the administration of nifedipine, a calcium 
channel blocker, able to suppress the beneficial effect of hypoxic 
vasoconstriction [47].  
Other bronchodilators, like ipratropium bromure or aminophylline, acting 
through different mechanisms of action, did not change VA/Q balance [45,48]. 
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Figure 1. 
Ventilation-perfusion distributions. Ventilation (○) and perfusion (●) are 
plotted against VA/Q ratio on a logarithmic scale in a resting young healthy 
subject breathing room air. Both curves are centred (first moment) around a 
VA/Q ratio of 1 and they are narrow (second moment). No perfusion to low 
VA/Q units (VA/Q ratio<0.1) nor ventilation to high VA/Q units (VA/Q ratio>10) 
are observed. Note also the absence of shunt. Each individual data point 
represents a particular amount of blood flow (●) or alveolar ventilation (○) to 
the corresponding pulmonary compartment (VA/Q ratio). Total cardiac output 
corresponds to the sum of the 50 blood flow points and total alveolar 
ventilation is the sum of the 50 ventilation points. ⋅ 
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Figure 2. 
With this MIGET modality mixed expiratory gas and arterial blood samples 
are collected; the inert gases solution is infused into a peripheral superficial 
vein. Through the arterial catheter the dye dilution is detected after 
indocyanine green bolus (5 mg of dye in 1 ml of water ) is rapidly flushed into 
the venous catheter and arterial blood is withdrawn at a constant rate of 20 
ml·min-1. ⋅ 
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Figure 3. 
A) Ventilation-perfusion distribution in patient with emphysema-type COPD. 
Note the bimodal pattern of ventilation distribution (○) with areas with high 
VA/Q ratio. B) Ventilation-perfusion ratio distribution in a patient with 
bronchitis-type COPD. The blood flow distribution (●) is bimodally shaped 
due to the presence of alveolar units with low V/Q ratio. ⋅ 
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 INTRODUCTION⋅ 
 
Adenosine 5’-monophosphate (AMP) is a natural nucleoside and 
mediator of airway inflammation increasingly used in inhalational challenge 
tests even though its pathophysiology remains insufficiently understood. It is 
a potent indirect agent inducing bronchoprovocation through the activation of 
inflammatory pathways at the level of bronchial surface and through local or 
central neuronal reflexes.[1-3]  
It has been suggested that AMP is a more potent inflammatory mediator than 
methacholine (MCh), a well-known bronchoconstrictive agent directly acting 
on airway tone. Compared to direct agents such as MCh and histamine, an 
AMP challenge could reproduce the lung function abnormalities 
spontaneously occurring during asthma attacks and better detect the 
inflammatory events of the disease at both central and peripheral airways.[4-
8]  
Accordingly, we hypothesized that AMP challenge in asthmatic patients could 
evoke greater gas exchange abnormalities and a different cellular response 
to that induced by MCh. There is evidence for a partial dissociation between 
expiratory airflow obstruction and gas exchange disturbances in acute 
asthma, since spirometric abnormalities, that mainly reflect narrowing in large 
and middle-sized airways, do not run in parallel to gas exchange 
abnormalities, better correlated to more peripheral airways dysfunction. [9-
11]  
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On this basis we used the multiple inert gas elimination technique (MIGET) to 
comprehensively assess pulmonary gas exchange and induced sputum 
cellular composition after AMP and MCh challenges producing an equivalent 
degree of bronchoconstriction. The comparison of the results obtained by the 
two challenges could facilitate a better insight into the pathophysiology of 
AMP and asthma.⋅ 
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MATERIAL AND METHODS⋅ 
 
Study population. Twelve non-smokers patients (5 females) with 
stable mild asthma were recruited for the study, as approved by the Ethical 
Research Committee at Hospital Clínic of Barcelona (age, 25±1 yr; FEV1, 
3.7±0.2 L [92±4% predicted], FEV1/FVC, 80±3%; PD20, 0.4±0.2 µmol). All 
subjects gave informed written consent after the purpose, risks and potential 
benefits of the study were explained to them. Inclusion criteria were: age 
between 18 and 45 yr; diagnosis of bronchial asthma according to GINA 
criteria [12]; FEV1>70% predicted (>1.5 L); a positive MCh (PD20<1.9 µmol) 
bronchial challenge on their first visit; absence of respiratory co-morbidities or 
any systemic or cardiopulmonary disease other than asthma; no asthma 
exacerbation within the last 6 weeks before the study; no treatment with 
systemic glucocorticosteroids in the previous 3 months. One patient received 
regular inhaled glucorticosteroids (budesonide, 400 µg b.i.d.) and two 
patients fixed inhaled combination therapy (budesonide/formoterol, 320/9 µg 
b.i.d.). All patients referred use of rescue short-acting β2-agonists. 
 
Study design. A randomized, double-blinded, cross-over design was 
used. After a first visit to evaluate the clinical and functional status, a sample 
of induced sputum was collected in a second visit, one week later. Then, 
after another week, the patients were challenged with AMP and MCh (Sigma-
Aldrich Química SA, Madrid, Spain), using a nebuliser attached to a breath-
activated dosimeter (Spira Elektro2, Respiratory Care Center, Finlandia), one 
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week apart. The nebuliser was set to nebulise for 0.6 s at a pressure of 200 
kPa with a flow of 0.6 L/s. During the challenges the patients breathed room 
air 1and were seated in an armchair. All asthma medication was withheld for 
48 h before arrival to the laboratory and patients were asked to refrain from 
caffeine-containing beverages/foods for at least 12 h before testing. After 
ensuring steady-state conditions, a set of duplicate measurements of all 
variables was obtained (baseline). Maintenance of steady-state conditions 
was demonstrated by stability (±5%) of both ventilatory and haemodynamic 
variables, and by the close agreement between duplicate measurements of 
mixed expired and arterial O2 and CO2 (within ±5%). The patients were then 
challenged with AMP/MCh following the recommended standardized 
procedures. [13-15] Doubling concentrations of AMP/MCh (from 0.39 to 400 
mg/dL) were administered by 5 consecutive dosimeter inhalations until the 
30% fall in FEV1 was achieved; at this point, resistance of respiratory system 
(Rrs) was also measured. Duplicate measurements were repeated after 5, 
15, and 45 min. All sets consisted in the following steps in sequence: FEV1, 
Rrs and ventilatory recordings; inert and respiratory gas sampling; and, 
haemodynamic recordings. Four hours after the beginning of each AMP/MCh 
challenge, induced sputum was collected. No patient needed rescue 
medication with short-acting bronchodilators during or immediately after the 
end of the study. ⋅ 
 
Measurements. On the day of the study, forced spirometry (CPF-S; 
Medical Graphics Corporation, St. Paul, MN USA) was performed according 
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to ATS recommendations, using our own predicted equations.[16][17] Rrs, 
PaO2, PaCO2 and pH, the alveolar-arterial PO2 difference (AaPO2), oxygen 
uptake (VO2) and carbon dioxide production (VCO2), minute ventilation (VE) 
and respiratory rate (RR) were measured, or calculated, as previously 
described. [18] MIGET was used to estimate the distributions of VA/Q ratios 
without sampling mixed venous inert gases. Cardiac output was directly 
measured by dye dilution technique (indocyanine green), in the customary 
manner.[18-19] A three-lead electrocardiogram, heart rate (HR) and systemic 
arterial pressure (Ps) and arterial oxygen saturation (SaO2) through a 
pulseoximeter (HP M1020A, Hewlett-Packard, Boblingen, Germany) were 
continuously recorded throughout the whole study (HP 1046A Monitor, 
Hewlett-Packard, Waltham, MA, USA). ⋅ 
 
Induced sputum. We performed the inhalation for the same period (7 
min) of increasing concentrations of hypertonic saline (3%, 5%, 7%) following 
the technique described by Pizzichini et al.[20] The procedure was stopped 
when an adequate sputum sample was collected (approximately 1 g of 
plugs), or if troublesome symptoms were present. The sputum was 
processed within 30 and 120 min from the collection of the more viscid 
proportions of the sputum (plugs). The reproducibility of measurements was 
calculated by the intraclass correlation coefficient. In two patients, sputum 
data were not available due to their poor viability (<50%). Interleukin-8 (IL-8) 
in sputum supernatants was also assessed. 
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Statistical analysis. Results are expressed as mean±SE and 95% 
confidence interval (CI). The effects of AMP and MCh challenges on the 
different end-point variables were assessed by a two-way repeated analysis 
of variance (ANOVA). Whenever there was a significant difference, post hoc 
comparisons at each time point were performed using paired t-test. Sputum 
cell differences were assessed using Paired t-test. Pearson’s rank test was 
used for correlations. All analyses were performed with SPSS version 10.1 
(SPSS Inc, Chicago, IL, USA). Statistical significance was set at p<0.05 in all 
instances.⋅ 
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RESULTS⋅ 
 
Baseline conditions. There were no clinical or functional differences 
between MCh and AMP study days, all patients having normal VA/Q 
distributions (Table 1).[21] 
 
Lung Function after AMP/MCh challenges. Along with a comparable 
degree of bronchoconstriction (FEV1 fall: AMP, 35±2%; MCh, 37±2%; Rrs 
increase: AMP, 114±18%; MCh, 92±13%) both AMP and MCh challenges 
(cumulative doses, 6.67±13.33 mg and 0.15±0.13 mg) produced, at 5 min, 
similar gas exchange abnormalities, as shown by a decreased PaO2 (by 
31±3% and 32±3%) and an increased AaPO2, respectively (Table 2). The 
arterial oxygenation defects observed after both challenges were essentially 
caused by mild-to-moderate VA/Q imbalance, as reflected by increases in the 
dispersion of blood flow (Log SDQ, normal values, ≤0.60 [21]) and DISP R-E* 
(normal values, ≤3.0) (Table 2).[22] Broadened unimodal VA/Q patterns were 
observed in each participant. All these abnormalities showed at 15 and 45 
min a similar trend to recover after both challenges, except for a mild, 
residual, increased Rrs and AaPO2 observed at the last time point. By 
contrast, compared with MCh, AMP induced at 5 min increases in VO2 (by 
10±4%) and in QT (by 20±8%) (p<0.05 each); VO2 also resulted increased at 
45 min and QT at 15 min (Table 2).  
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Induced sputum. Four hours after AMP challenge neutrophils 
increased from 48±7% to 62±6%, (p<0.05) without other associated cellular 
changes (Table 3; Figure 1). By contrast, the cellular composition of induced 
sputum collected after MCh did not vary from baseline. The number of 
neutrophils in the baseline sputum showed a significant correlation with the 
concentration of IL-8 in the supernatant (r, 0.769; p<0.01) and with the 
increases in Rrs (r, 0.803; p<0.01) and AaPO2 (r, 0.657; p<0.05) observed 
after AMP challenge (Figure 2). A significant correlation was also shown 
between the baseline concentration of IL-8 in the sputum supernatant and 
the increase in Rrs at 5 min on AMP study day (r, 0.726; p<0.01). ⋅ 
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DISCUSSION⋅ 
 
There were two major novel findings in our study. Firstly, we 
demonstrated that AMP bronchoconstriction provoked, in patients with mild 
asthma, identical gas exchange abnormalities and VA/Q imbalance than MCh 
while undergoing an equivalent degree of airflow limitation. Secondly, the 
AMP challenge caused mild neutrophilia in induced sputum 4 hours after 
challenge. In addition, we confirmed that AMP is an effective and clinically 
well-tolerated bronchoconstrictive agent that associates haemodynamic and 
metabolic effects.[6] 
There is strong evidence in the literature that bronchial responsiveness to 
AMP correlates well with airways inflammatory markers (blood and sputum 
eosinophils) and that reflects acute changes in airways inflammation, as seen 
by therapeutical (corticosteroids) and/or environmental (allergens avoidance) 
interventions.[4][7][8] On this basis, we postulated that AMP challenge, by 
acting through inflammatory mechanisms, could be more influential in small, 
peripheral airways, thereby inducing greater gas exchange and VA/Q 
abnormalities than MCh, a more centrally acting agent. Notwithstanding, our 
study failed to confirm our hypothesis, in that after both challenges patients 
showed a similar degree of hypoxaemia and increased AaPO2, due to 
identical VA/Q mismatching. It is generally held that gas exchange 
impairment in asthma is mainly induced by small airways, but experimental 
studies have shown that the VA/Q imbalance becomes much more disrupted 
with larger airways narrowing. It is highly likely that the intense level of 
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bronchoconstriction (∼ PD30) could hide any difference in VA/Q mismatching 
due to the different bronchoconstrictive mechanisms of action of AMP and 
MCh. ⋅ 
Our study demonstrated that AMP is a well-tolerated effective 
bronchoconstrictive agent, with an average cumulative dose ratio to MCh of 
approximately 45. Furthermore, AMP challenge induced increases QT and 
VO2 at different points in time, possibly as a consequence of the inotropic 
effects of AMP and its metabolite adenosine, via the activation of specific 
receptors (A2).[23] These complementary effects need to be taken into 
account in the management of asthmatic patients with potential 
cardiovascular disturbances.
 
In conjunction with the functional abnormalities alluded to, there was a 
significant mild increase in neutrophils in induced sputum 4 hours after AMP 
inhalation. Although there is certain evidence of a correlation between 
cellular composition of the sputum and AMP responsiveness in asthmatic 
patients, there are few data regarding the effects of AMP challenge on 
induced sputum.[4] Van der Berge and coworkers showed an increase in 
eosinophils in the sputum collected 1 hour after AMP inhalation in patients 
with mild asthma, at variance with our finding.[24] Differences in patients’ 
characteristics, inhalational procedures and, above all, in the time course of 
sputum collection after challenge might explain in part  these discrepancies. 
Notwithstanding, it might be possible that our finding reflect a late, 
neutrophilic stage of the inflammatory process triggered by AMP challenge. 
By contrast, the study of Van der Berge may well reflect an earlier phase, 
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mainly characterised by eosinophilic involvement. [24] In a previous work 
with mild asthmatic patients, we observed an increase in neutrophils in the 
sputum 4 hours after challenge with platelet-activating factor (PAF), a potent 
inflammatory mediator possibly involved, but never sufficiently proven, in the 
pathogenesis of asthma.[25] This late, neutrophilic response to PAF may 
thus support our hypothesis about the inflammatory response to AMP 
challenge. A different study in asthmatic patients challenged with inhaled 
leukotriene D4 (LTD4), demonstrated an increase of eosinophils in the 
sputum 4 hours after challenge, also shown by our group at a shorter time 
point (75 min) after LTD4. [26][27] The activation of a different pathway of 
bronchoconstriction (direct mechanisms of action) could explain such 
different findings. A confirmation of the validity of our “neutrophilc model of 
bronchoconstriction” comes from the interesting observation that a greater 
number of neutrophils in the baseline sputum and  higher concentrations of 
IL-8 in the sputum supernatant, a chemotactive factor of neutrophils, 
correlated closely with the mechanic (Rrs) and gas exchange (AaPO2) 
abnormalities provoked by AMP. ⋅In summary, for the same degree of 
bronchoconstriction, AMP challenge did not induce more marked gas 
exchange disturbances than MCh, but caused mild neutrophilia in induced 
sputum at 4 hours after challenge.  
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Table 1. Basal conditions on AMP and MCh days. 2 
 
 
 
Rrs: respiratory system resistance; PaO2: arterial oxygen partial pressure; 
AaPO2: alveolar-arterial oxygen partial pressure difference; VO2: oxygen 
uptake; QT: cardiac output; Log SDQ: dispersion of pulmonary blood flow 
(dimensionless); DISP R-E*: dispersion of retention minus excretion inert 
gases corrected for dead space (dimensionless). 
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AMP MCh 
FEV1, L 3.2 ± 0.2 3.2 ± 0.2 
FEV1, % predicted 85 ± 6 83 ±  6 
FEV1/FVC % 81 ± 3 81 ± 2 
Rrs, cm H2O·L-1·s 4.6 ± 0.3 4.6 ±  0.4 
PaO2, KPa 13.4 ± 0.3 13.5 ±  0.2 
AaPO2, KPa 0.52 ± 0.16 0.27 ±  0.12 
VO2, mL·min-1 197 ± 9 186 ± 12 
QT, L·min-1 5.7 ± 0.3 5.6 ±  0.3 
Log SDQ 0.47 ± 0.04 0.44 ±  0.02 
DISP R-E* 3.15 ± 0.49 2.38 ±  0.26 
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Table 2. Mean differences (and 95% IC) after AMP and MCh challenges. 3 
 
  5 min 15 min 45 min p value† 
 
AMP -1.1 (-1.3 to -1.0) -0.6 (-0.8 to -0.5) -0.3 (-0.4 to -0.1) NS FEV1, L 
MCh -1.2 (-1.4 to -1.0) -0.7(-0.8 to -0.5) -0.2 (-0.4 to -0.1)  
Rrs, cm H2O·L-1·s AMP 4.9 (3.4 to 6.5) 3.7 (0.9 to 6.6) 1.6 (0.2 to 3.0) NS 
 MCh 4.3 (2.9 to 5.6) 2.7 (1.4 to 3.9) 1.9 (1.1 to 2.7)  
PaO2, KPa AMP -4.1 (-4.9 to –3.2) -2.1 (-3.1 to –1.3) -0.4 (-1.2 to 0.5) NS 
 MCh -4.3 (-5.3 to –3.3) -2.7 (-3.9 to –1.5) -0.9 (-1.9 to 0.1)  
AaPO2, KPa AMP 3.3 (2.7 to 4.0) 1.7 (0.9 to 2.5) 0.7 (0.4 to 1.6) NS 
 MCh 3.7 (2.8 to 4.5) 2.3 (1.6 to 3.1) 0.8 (0.3 to 1.3)  
VO2, mL·min-1 AMP 21 (2 to 40)‡ 10 (-6 to 26) 17 (0.0 to 34)‡ <0.05 
 MCh 8 (-8 to 23) 1 (-12 to 15) -3 (-22 to 16)  
QT, L·min-1 AMP 1.0 (0.2 to 1.8)‡ 0.6 (0.1 to 1.1)‡ 0 (-0.3 to 0.3) <0.01 
 MCh 0.2 (-0.2 to 0.5) 0 (-0.45 to 0.49) -0.2 (-0.6 to 0.1)  
Log SDQ AMP 0.27 (0.18 to 0.36) 0.13 (0.03 to 0.23) 0.05 (0.04 to 0.14) NS 
 MCh 0.38 (0.26 to 0.49) 0.27 (0.17 to 0.36) 0.12 (0.06 to 0.18)  
DISP R-E* AMP 3.77 (2.25 to 5.28) 1.41 (0.22 to 2.60) 0.33 (-1.45 to 0.80) NS 
 MCh 4.59 (3.09 to 6.08) 3.26 (1.75 to 4.77) 1.65 (0.81 to 2.49)  
 
 
For abbreviations see Table 1. 
†
 Significance of the interaction between the effects of the bronchoprovocative agent and time course (repeated measures ANOVA);  
‡
 p<0.05 compared with MCh (paired t-test). 
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 Table 3. Induced sputum analysis before and after AMP and 
MCh challenges4 
 
 
  Baseline AMP MCh 
Total Cell Count, x104·g-1 1,124 ± 215 1,136 ± 278  985 ± 230 
Cell viability, %  71± 3 71 ± 5      71 ± 3 
Squamous cells, %   3 ± 1   4 ± 1  4 ± 1 
Macrophages, %       36 ± 5 31 ± 5      43 ± 8 
Lymphocytes, %  4 ± 0   2 ± 1  4 ± 1 
Neutrophils, %       48 ± 7  62 ± 6*      47 ± 9 
Eosinophils, %       10 ± 5   4 ± 1  5 ± 3 
IL-8, pg/mL   2204 ± 702   1624 ± 522  1246 ± 206 
 
 
Values are mean ± SE; * p: 0.02 compared with baseline (paired t-test). 
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 INTRODUCTION 
 
Episodes of exacerbations are the most common complications in the 
natural history of chronic obstructive pulmonary diseases (COPD). These 
episodes are always characterized by a significant worsening in pulmonary 
gas exchange that results in severe hypoxemia with or without hypercapnia 
[1]. Both arterial hypoxemia and hypercapnia are modulated by a complex 
interplay between intrapulmonary (ventilation-perfusion [VA/Q] mismatching) 
and extrapulmonary (minute ventilation [VE], cardiac output [QT], and oxygen 
consumption [VO2]) factors [2]. It has been demonstrated that the principal 
mechanism of arterial hypoxemia in patients with COPD is VA/Q imbalance, 
both in stable conditions and during exacerbations [3]. 
Short-acting β2-agonists [SABAs] are one of the mainstays of treatment of 
COPD exacerbations [4].  
SABAs are potent bronchodilators but also vasoactive agents  with inotropic 
and chronotropic effects, hence potentially influencing different aspects of 
cardiopulmonary function [5]. However, a comprehensive assessment of the 
effects of such bronchodilators on intrapulmonary and extrapulmonary 
determinants of gas exchange during COPD exacerbations remains 
unsettled. Accordingly, we investigated in patients with COPD exacerbations 
needing hospitalization the effects of a therapeutic dose of nebulized 
salbutamol (5.0 mg) on pulmonary gas exchange using the multiple inert gas 
elimination technique (MIGET). 
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The same patients were studied during stable conditions, 2-3 months after 
their episode of exacerbation in order to assess how the factors contributing 
to gas exchange abnormalities vary during recovery in response to nebulized 
salbutamol and to facilitate, therefore, a better insight into the 
pathophysiology of COPD.   
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 MATERIAL AND METHODS⋅ 
 
Study population. We studied 20 patients (1 female; 5 smokers, 15 
ex-smokers, 58 ± 8 pack-years), mean (± SEM) age 67 ± 2 yrs who fulfilled 
the criteria for the diagnosis of COPD [6] and were admitted to hospital 
because of an acute exacerbation of their disease, according to the decision 
of the attending physicians. At the inclusion in the study ten patients reported 
a history of more than 10 yrs of COPD, 6 patients between 5 and 10 yrs, 4 
patients less than 5 yrs. Pulmonary function tests performed during stable 
conditions (before or after 2-5 months the exacerbation episode) showed a 
severe airflow obstruction (post-bronchodilator FEV1: 39 ± 4% of pred.; FVC: 
2.8 ± 0.2 L; FEV1/FVC ratio: 0.40 ± 0.03), a normal total lung capacity (TLC: 
108% ± 4 of pred.) a severe lung hyperinflation (RV: 187 ± 13% of pred.; 
IC/TLC: 0.28 ± 0.03) and a moderate-to-severe reduction of carbon 
monoxide transfer factor (DLCO: 53 ± 4% of pred.; KCO: 65 ± 5% of pred.). 
Patients showed moderate hypoxemia and mild hypercapnia (PAO2: 65.7 ± 
2.7 mmHg; PaCO2: 42.1 ± 1.5 mmHg). As two patients died for medical 
complications before completing the study (one for an acute intestinal 
occlusion, the other during an exacerbation of the respiratory disease) and 
other two were lost at follow-up (multiple re-exacerbations) data of lung 
volumes, DLCO and arterial blood gases in stable conditions are available 
only from 16 patients. All patients were in GOLD stages III or IV. On 
admission to the emergency room, patients showed moderate hypoxemia 
(PaO2 62.2 ± 2.2 mmHg) and hypercapnia (PaCO2 44.4 ± 3.0 mmHg) with a 
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normal arterial pH (7.42 ± 0.01) even considering that in 6 and 3 cases, 
respectively, the first measurement of arterial gases was performed with 
supplemental oxygen of 1 and 2 L/min. Patients with complications 
(pneumonia, pulmonary thromboembolism, pleural effusion) and with 
comorbidities, like bronchial asthma, lung cancer and cardiovascular 
diseases or requiring mechanical ventilation were excluded from the study. 
All patients received standard treatment with supplemental oxygen, inhaled 
bronchodilators (salbutamol and ipratropium bromure), intravenous 
corticosteroids and antibiotics. The mean length of hospital stay was of 7 ± 1 
days. 
 
Study design. Patients were studied within the first 4 days (median, 
3) of hospitalization, when they were able to breathe through the breathing 
circuit and 2-3 months after hospital discharge, once they were in stable 
condition and in absence of any other re-exacerbation of the respiratory 
disease from the first study. Medication as decided by the attending 
physician was maintained unmodified. Only one patient received 
supplemental oxygen therapy at 1.5 L/min (16 hours daily) after the 
exacerbation. During the studies all patients were afebrile, breathed room 
air7and were seated in an armchair. Measurements were performed before 
(at least 6 hrs after the last dose of inhaled bronchodilators and intravenous 
corticosteroids) and at 30 and 90 min after nebulization of 5mg of salbutamol. 
After ensuring steady-state conditions, a set of duplicate measurements of all 
variables was obtained at each time point. Maintenance of steady-state 
conditions was demonstrated by stability (±5%) of both ventilatory and 
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haemodynamic variables, and by the close agreement between duplicate 
measurements of mixed expired and arterial O2 and CO2 (within ±5%). All 
sets of measurements consisted in the following steps in sequence: FEV1, 
forced vital capacity (FVC), inspiratory capacity (IC) and ventilatory 
recordings; inert and respiratory gas sampling; haemodynamic recordings 
(systemic arterial pressure; cardiac output, QT; heart rate, HR).  
Spontaneous sputum was collected before and between 30 and 90 min after 
salbutamol.   
 
Measurements. On the day of the study, forced spirometry and 
Inspiratory capacity (IC)  (CPF-S; Medical Graphics Corporation, St. Paul, 
MN USA) were performed according to ATS/ERS recommendations, using 
our own predicted equations.[7][8] PaO2, PaCO2 and pH, alveolar-arterial 
PO2 difference (AaPO2), oxygen uptake (VO2) and carbon dioxide production 
(VCO2), minute ventilation (VE) and respiratory rate (f) were measured, or 
calculated, as previously described. [9] MIGET was used to estimate the 
distributions of VA/Q ratios without sampling mixed venous inert gases. 
Unfortunately, VA/Q data were lost for technical problems in 4 studies of the 
exacerbation phase and in one study of stable phase. QT was directly 
measured by dye dilution technique (indocyanine green), in the customary 
manner.[9][10] A three-lead electrocardiogram, heart rate (HR) and systemic 
arterial pressure and arterial oxygen saturation (SaO2) through a 
pulseoximeter (HP M1020A, Hewlett-Packard, Boblingen, Germany) were 
continuously recorded throughout the whole study (HP 1046A Monitor, 
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Hewlett-Packard, Waltham, MA, USA). Exhaled breath condensate (EBC) 
was also collected before and at 90 min after salbutamol using the 
EcoScreen (Jaeger, Germany), according to ATS/ERS recommendations.  
[11]   
Statistical analysis. Results are expressed as mean ± SE. The 
effects of nebulized salbutamol on the different end-point variables in each 
phases of the study (exacerbation and stable condition) were assessed by a 
one-way and two-ways repeated analysis of variance (ANOVA). Whenever 
there was a significant difference, post hoc comparisons at each time point 
were performed using paired t-test. All analyses were performed with SPSS 
version 11.1 (SPSS Inc, Chicago, IL, USA). Statistical significance was set at 
p<0.05 in all instances.⋅ 
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RESULTS 
 
Exacerbation.   
 
At baseline, patients showed a severe degree of bronchoconstriction (FVC, 
36 ± 2% of predicted; FEV1, 24 ± 2% of predicted), with high values of VE and 
f (Table 1). Mean PaO2 was moderately to severely reduced (range, 45.7 - 
76.0 mmHg) while PaCO2 was moderately increased (range, 33.3 - 68.2 
mmHg). Gas exchange abnormalities run in parallel with moderate-to-severe 
VA/Q imbalance: the dispersions of both blood flow (Log SDQ, range: 0.60 - 
1.75) and ventilation (Log SDV, range: 0.70 - 1.26) distributions and the 
overall index of VA/Q heterogeneity (DISP R-E*, range: 8.7 - 20.7) were 
increased (Table 1). Shunt (percentage of blood flow to units with VA/Q 
ratio<0.005) and areas with high (10 - 100) VA/Q ratios were negligible, while 
areas with low (<0.1, excluding shunt) VA/Q ratios and dead space (>100 
VA/Q ratios) were moderately increased. Patients showed increased QT and 
HR with normal values of mean arterial pressure (Ps) and O2 uptake (VO2). 
At 30 min, nebulized salbutamol significantly improved FEV1 (by 14%) and IC 
(by 10%), while VE and f remained stable. PaO2 and PaCO2 slightly 
decreased along further significant increases in AaPO2 (by 2.0 mmHg), in 
Log SDQ (by 7%) and in areas with low VA/Q ratios (by 27%). In addition, 
salbutamol increased QT (by 13%) and HR (by 11%) and decreased Ps (by 8 
mmHg). At 90 min, in comparison with baseline, FEV1, IC, were still 
increased; respiratory (PaO2, PaCO2, AaPO2) and inert (Log SDQ, Low VA/Q, 
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DISPR-E*) gas exchange indices showed a trend toward baseline. 
Hemodynamic changes (increased HR and decreased Ps) were still present 
at 90 min, except for QT that showed a trend toward baseline. VO2 remained 
stable during all the study. 
 
Stable conditions. ⋅ 
 
Nine patients of the initial sample were excluded from the second phase of 
the study for multiple re-exacerbations and two individuals, as previously 
described, died. The remaining nine patients repeated the study 14 ± 3 
weeks after discharge, once they were in clinical stable conditions. At 
baseline, as compared to exacerbation, patients had lower VE (p<0.05), a 
comparable f and a similar airflow obstruction but less hyperinflation, as 
shown by greater IC (p<0.02) (Table 2). Gas exchange impairment and VA/Q 
inequality were significantly minor under stable condition as shown by PaO2, 
AaPO2 and Log SDQ (p<0.05 each). Cardiac Output and HR (p<0.05), as 
expected, were lower than during exacerbation. No significant differences 
were observed in Ps and VO2. At 30 min, nebulized salbutamol induced 
significant increases in FEV1 (by 17%) and IC (by 17%) without any change 
in the ventilatory pattern (VE, f) (Table 3). We also observed significant 
decrease in PaO2 (by 6.7 mmHg) and increase of AaPO2 (by 5.3 mmHg), 
with an unchanged PCO2. Arterial deoxygenation was associated with a 
significant worsening in VA/Q imbalance as shown by increases in Log SDQ 
(by 15%) and DISP R-E* (by 33%). In addition, salbutamol induced 
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significant increases in QT (by 23%), HR (by 17%) and VO2 (by 24 mL/min) 
and decreased Ps (by 6 mmHg). At 90 min FEV1 and IC were still increased, 
the arterial deoxygenation (PaO2, AaPO2) was similar to 30 min, such as the 
increases in Log SDQ and DISPR-E* (Table 3). Also the hemodynamic 
changes (increased QT and HR, decreased Ps) were still present at 90 min, 
while VO2 returned to baseline. 
 
Comparison between exacerbation and stable COPD.  
 
By comparing the effects of salbutamol observed during both phases of the 
study (9 patients, 7 with complete VA/Q data) through a two-ways ANOVA 
analysis, we detected similar spirometric and hemodynamic responses, as 
shown by FEV1, IC and QT time courses in Figure 1. By contrast, whereas 
arterial oxygenation showed only negligible changes during the exacerbation, 
PaO2 in stable COPD decreased by 7 ± 2 mmHg at 30 min and by 6 ± 2 
mmHg at 90 min and AaPO2 increased by 5 ± 1 mmHg (30 min) and 6 ± 1 
mmHg (90 min) (p<0.01 each). Similarly, VA/Q inequality worsening after 
salbutamol resulted significantly greater and longer under stable conditions, 
as shown by DISP R-E* time course (Figure 1). In fact, during the 
exacerbation DISP R-E* increased by 6% at 30 min and returned to baseline 
at 90 min; by contrast under stable conditions we observed an increase of 
31% up to 90 min (p<0.05). ⋅ 
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DISCUSSION⋅ 
 
During COPD exacerbations nebulized salbutamol induced significant 
bronchodilator (increases in FEV1 and IC) and hemodynamic (increased QT 
and heart rate, decreased MAP) effects up to 90 min after nebulized 
salbutamol. We also observed a temporary, further, deterioration of VA/Q 
distribution accompanied by a mild gas exchange worsening 30 min after 
salbutamol. 
The same patients in stable convalescence showed a similar response to 
salbutamol in terms of spirometric and hemodynamic changes, even though 
at baseline they were in better clinical and functional conditions. By contrast, 
worsening in gas exchange and VA/Q imbalance were much greater in stable 
conditions and lasted up to 90 min after salbutamol. 
The strict relation between gas exchange and VA/Q imbalance has been 
widely investigated. Barberá and coworkers by studying COPD exacerbated 
patients, estimated that 46% of hypoxemia is attributable to VA/Q inequality, 
whether a 28% to the combined effect of increased VO2 and QT[3]. In our 
study VO2 did not appear to play a significant role in both phases of the study 
while QT was higher during the exacerbation. As QT increase is able to 
augment the oxygen concentration of mixed venous blood and potentially 
counterbalance the effects of VA/Q imbalance on arterial oxygenation, it has 
often supposed an important contribution of QT in determining PaO2 in COPD 
exacerbations.  
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By contrast, our study shows similar QT responses after salbutamol in both 
COPD exacerbation and stable convalescence, but a significant 
deoxygenation only in stable COPD, suggesting only a limited role of QT in 
determining PaO2. 
A worsening of arterial oxygenation and VA/Q balance after β2-agonists 
administration has been previously described and ascribed to the release of 
hypoxic pulmonary vasoconstriction [12-16]. Ringsted and coworkers, in 
comparison with our study, observed an analogous response of VA/Q 
distributions after the administration of intravenous terbutaline in stable 
COPD patients with a similar degree of bronchoconstriction[14]. Viegas  et al. 
also described similar data with the administration of nebulized fenoterol in 
stable COPD patients [16]. Our data confirm this hypothesis as PaO2 fall in 
stable conditions runs in parallel with the increased dispersion of pulmonary 
blood flow (Log SDQ), suggesting pulmonary vasodilatation.  
However, this phenomenon appears to be mild during COPD exacerbations 
as probably in presence of more hypoxemia, airflow obstruction, 
hyperinflation and higher hyperkinetic vascular state, the pulmonary vascular 
tone is more hypoxic and more constricted, hence less liable to 
vasodilatation. By contrast, under stable conditions gas exchange response 
to salbutamol is much greater as, in less hypoxemic conditions, the 
pulmonary vasculature is less constricted and more sensitive to 
vasodilatation i.e. hypoxic pulmonary vasoconstriction release and further 
VA/Q worsening. 
Similarly, the work of Ringsted showed minor VA/Q and gas exchange 
abnormalities in those patients who presented very severe airways 
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obstruction, likely because pulmonary vascular tone and its flexibility are 
limited in more advanced stages of COPD such as during exacerbations [15]. 
A clinical implication of this finding is that particular attention is necessary 
when SABA are administered to COPD patients as arterial oxygenation can 
temporarily worsen notwithstanding the general improvement of dyspnoea 
that is likely more related, to the degree of hyperinflation than to PaO2 [17]. 
In conclusion, this work by offering a complete and paired analysis of all 
parameters modulating respiratory gas exchange under different clinical 
conditions, clarifies effects and mechanisms of action of β2-agonists in COPD 
and, contemporary, underlies the central role of hypoxic pulmonary 
vasoconstriction in regulating VA/Q and gas exchange efficacy in COPD.  
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Table 1. Acute effects of salbutamol during COPD exacerbations (n= 20). 
 
 
Baseline 30 min 90 min p† 
FEV1, L 0.73 ± 0.06 0.83 ± 0.07** 0.81 ± 0.06** <0.01 
IC, L 1.62 ± 0.13 1.76 ± 0.13** 1.77 ± 0.13** <0.01 
VE, L/min 8.6 ± 0.4 8.9 ± 0.4 8.6 ± 0.5 NS 
f, min-1 17 ± 1 18 ± 1 18 ± 1 NS 
PaO2, mmHg 61.1 ± 2.0 59.1 ± 2.0 60.7 ± 2.0 NS 
PaCO2, mmHg 46.2 ± 2.1 44.7 ± 1.9** 44.3 ± 1.6 <0.02 
AaPO2, mmHg 36.5 ± 2.5 38.5 ± 2.3** 35.2 ± 2.5 <0.01 
HR, min-1 90 ± 3 99 ± 4** 95 ± 3** <0.01 
Ps, mmHg. 95 ± 3 87 ± 2** 89 ± 2** <0.01 
QT, L/min 7.1 ± 0.4 8.0 ± 0.5** 7.3 ± 0.4 <0.01 
VO2, mL/min 242 ± 7 249 ± 8 257 ± 8 NS 
Shunt, % of QT 1.8 ± 0.7 2.0 ± 0.8 1.7 ± 0.7 NS 
Low VA/Q, % QT 9.5 ± 2.4 12.6 ± 3.0** 8.7 ± 2.2 <0.05 
Log SDQ 1.17 ± 0.07 1.23 ± 0.07** 1.13 ± 0.08 <0.01 
Log SDVE 1.00 ± 0.04 0.99 ± 0.04 0.98 ± 0.04 NS 
High VA/Q, % VE 1.3 ± 0.7 1.4 ± 0.7 1.1 ± 0.4 NS 
Dead space, % VE 34.5 ± 2.0 35.8 ± 1.9 35.2 ± 2.0 NS 
DISP R-E* 14.9 ± 0.8 15.9 ± 0.9 14.0 ± 1.0** <0.01 
 
† Repeated measures ANOVA; ** p<0.05, post-hoc analysis (paired t-test) compared with baseline. Definition of the abbreviations. 
f: respiratory rate; AaPO2: alveolar-arterial oxygen difference; MAP: mean systemic arterial pressure; Shunt, % of QT: % of QT to 
lung units with VA/Q ratios<0.05. Low VA/Q, % QT: % of QT to lung units with VA/Q ratio< 0.1, excluding shunt; Log SDQ: dispersion 
of blood flow distribution (normal, 0.30-0.65); Log SDV: dispersion of the alveolar ventilation distribution (normal, 0.30-0.60); High 
VA/Q, % VE: % of VA to lung units with VA/Q ratio>10, excluding dead space; dead space: % of VA to lung units with VA/Q ratio> 
100; DISPR-E*: dispersion of retention minus excretion inert gases corrected for dead space (normal, ≤ 3).   
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Table 2. Spirometric, hemodynamic and gas exchange data during exacerbations and under stable 
conditions (n= 9).  
 
 
 Exacerbation 
 
Stable 
Conditions 
 
p† 
FEV1, L 0.76 ± 0.08 0.97 ± 0.16 NS 
FEV1, % pred. 24 ± 2 31 ± 4 NS 
FVC, L 2.15 ± 0.18 2.42 ± 0.25 NS 
FEV1/FVC% 51 ± 3 54 ± 5 NS 
IC, L 1.56 ± 0.15 1.99 ± 0.26 <0.02 
VE, L/min 8.9 ± 0.5 7.3 ± 0.5 <0.05 
f, min-1 17 ± 1 17 ± 2 NS 
PaO2, mmHg 63.5 ± 3.0 70.7 ± 4.4 <0.05 
PaCO2, mmHg 43.0 ± 1.9 43.4 ± 1.8 NS 
AaPO2, mmHg 36.9 ± 4.1 26.5 ± 3.1 <0.01 
QT, L/min 6.5 ± 0.4 5.7 ± 0.5 NS 
HR, min-1 81 ± 4 73 ± 4 <0.05 
Ps, mmHg 90 ± 4 96 ± 4 NS 
VO2, mL/min 246 ± 11 211 ± 12 NS 
SHUNT  % QT 0.5 ± 0.4 0.9 ± 0.5 NS 
Low VA/Q % QT 8.8 ± 3.6 4.5 ± 2.6 NS 
Log SD Q 1.24 ± 0.11 0.98 ± 0.09 <0.05 
Log SD VE 0.93 ± 0.05 0.91 ± 0.07 NS 
High VA/Q  % VE 0.37 ± 0.23 1.63 ± 0.82 NS 
Dead Space  % VE 35 ± 3 33 ± 4 NS 
DISP R-E* 14.58 ± 1.40 11.72 ± 1.39 NS 
 
† Paired t-test analysis; (n= 7 for VA/Q variables). Definition of the abbreviations: see Table 2. 
                                                
 
 Polverino E. et al. COPD and salbutamol 
 Table 3. Effects of salbutamol during stable conditions (n= 9). 
 
 
 Baseline 
 
30 min 90 min p† 
FEV1, L 0.97 ± 0.16 1.13 ± 0.20** 1.16 ± 0.20** <0.01 
FEV1, % pred. 31 ± 4 36 ± 5** 36 ± 9** <0.01 
FVC, L 2.42 ± 0.25 2.57 ± 0.27** 2.62 ± 0.29** <0.05 
FEV1/FVC% 40 ± 5 45 ± 5** 44 ± 5** <0.05 
IC, L 1.99 ± 0.26 2.26 ± 0.28** 2.24 ± 0.28** <0.01 
VE, L/min 7.3 ± 0.5 7.9 ± 0.5 7.4 ± 0.4 NS 
f, min-1 16 ± 2 15 ± 1 16 ± 1 NS 
PaO2, mmHg 70.7 ± 4.4 63.2 ± 3.4** 64.3 ± 3.2** <0.05 
PaCO2, mmHg 43.4 ± 1.8 43.0 ± 1.6 42.6 ± 1.7 NS 
AaPO2, mmHg 26.5 ± 3.1 32.0 ± 2.8** 33.6 ± 3.0** <0.01 
QT, L/min 5.7 ± 0.5 7.0 ± 0.6** 6.5 ± 0.5** <0.01 
VO2, mL/min 211 ± 12 232 ± 11** 213 ± 14 <0.01 
HR, min-1 73 ± 4 85 ± 4** 82 ± 3** <0.01 
Ps, mmHg 96 ± 4 91 ± 4** 89 ± 4** <0.05 
SHUNT  % QT 0.84 ± 0.44 1.36 ± 0.50** 1.32 ± 0.54** <0.05 
Low VA/Q % QT 4.11 ± 2.43 8.06 ± 3.54 9.61 ± 3.92 NS 
Log SDQ  0.96 ± 0.09 1.12 ± 0.13** 1.15 ± 0.13** <0.05 
Log SDV 0.91 ± 0.06 1.02 ± 0.07 0.96 ± 0.06 NS 
High VA/Q  % V 1.39 ± 0.73 0.98 ± 0.71 0.89 ± 0.68 NS 
Dead Space  % V 32.80 ± 4.10 34.21 ± 3.63 35.56 ± 2.89 NS 
DISP R-E* 11.35 ± 1.31 14.68 ± 1.48 14.14 ± 1.47 <0.01 
† Repeated measures ANOVA; ** p<0.05, post-hoc analysis (paired t-test) compared with baseline; (n=8 for VAQ data).  
Definition of the abbreviations: see Table 1. 
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⋅
 Conclusions and future perspectives 
⋅
 
 
The main research work has been focused on the basic pathophysiology of 
gas exchange of two very common respiratory diseases, asthma and chronic 
obstructive pulmonary disease. 
Particularly, research on bronchial asthma has been conducted through a 
model of bronchial challenge with adenosine 5’monophosphate that is 
considered today innovative as it can simulate a real asthma attack through 
the activation of indirect inflammatory and bronchoconstrictive patterns. In 
particular we wanted to investigate the old hypothesis of dissociation 
between large and medium sized airways, accounting for the obstructive 
spirometric abnormalities of asthma, and small airways, where inflammatory 
and remodelling processes can affect gas exchange efficacy (PaO2, AaPO2, 
VA/Q balance) independently by the bronchomotor tone [1-2]. The existence 
of “a small airways disease” in asthma is an issue giving rise to an increasing 
interest of chest physicians. Unfortunately only MIGET studies of Wagner PD 
and Rodriguez Roisin R could give some scientific support to this hypothesis 
that remains difficult to detect as large airways tone influences the insight of 
pathological events affecting the more peripheral part of the lung. In addition, 
if we exclude few invasive methodologies analysing directly lung tissue (for 
instance, pulmonary biopsy), there are few possibilities to investigate 
pathophysiology of peripheral airways. A big contribution has been given by 
MIGET providing a picture of ventilation and distributions in functional lung 
units without interfering with broncho-motor and vascular tones. Even being a 
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difficult and not practical technique it gives, with the necessary experience 
and practice, a fundamental contribution to clinical research. Today we 
consider of great interest the investigation on small airways through the 
integration of MIGET with old and newer other techniques in order to obtain a 
better control and follow-up of the disease and to verify new therapeutical 
approaches. ⋅On this base a new research protocol on mild-to-moderate 
asthma has been proposed in order to study patients with intermittent 
symptoms, treated with combined inhaled therapy (2-agonists - 
corticosteroids), by using different techniques able to provide some functional 
and morphological information on pathological processes of small airways. In 
particular we plan to study: 
1. Flow-volume curves, with particular attention at medium and low volumes 
(MEF and FEF 25-50-75];  
2. Closing volume; an increased value of closing volume or closing capacity 
expresses the precocious collapse of lower parts of the lungs and seems 
to be a good marker of small airways obstruction even in presence of a 
normal FEV1; 
3. Bronchial and alveolar production of NO; exhaled NO is considered a 
good marker of airways inflammatory disorders and a recent 
mathematical model is able to discriminate the bronchial and alveolar 
production by applying different resistances at mouth. 
4. Respiratory gases and AaPO2, through the direct measurement of 
respiratory rate (VCO2/VO2); ⋅ 
5. MIGET; 
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6. Pulmonary ventilation scan. It analyses pulmonary ventilation distribution 
through the inhalation of TC99-labelled micro-particles; the recent 
technique, developed in the Cardio-Thoracic Department of Pisa, avoids 
adequately spotting images due to large airways deposition of the 
particles and allows a good definition of more peripheral ventilated areas.  
The aim is to evaluate the presence of VA/Q and gas exchange 
abnormalities, which remain commonly unidentified, beside mild spirometric 
abnormalities and to correlate them with the other parameters considered, 
hoping to find a new definition of small airways diseases in asthma through 
the combination of new and old techniques and new parameters specific for 
small airways able to open to new follow-up and therapeutical approaches. 
 
 
The other respiratory disease object of the present investigation with 
the contribution of MIGET is that heterogeneous group of clinical, functional 
and biological conditions called “chronic obstructive pulmonary diseases”, 
including, basically, chronic bronchitis, emphysema and, according to some 
authors, chronic asthma when flow obstruction reversibility is lost.  
Particularly, this clinical research experience has underlined the complexity 
of the interaction among intra pulmonary and extra pulmonary factors 
determining pulmonary gas exchange in COPD. Few methodologies can 
probably provide so complete information about pathophysiological 
mechanisms of a respiratory disease as MIGET. In addition, the model of 
study adopted in this work has two major advantages: ⋅ 
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- it provides a better knowledge of β2-agonists that are not only 
bronchodilators but also vasoactive and inotropic agents profoundly 
influencing, therefore, the general hemodynamic balance; ⋅ 
- it underlines the central role of pulmonary circulation and vascular tone 
regulation in pathophysiology of COPD, whereas the “vascular side” of 
respiratory diseases is often forgotten and airways abnormalities are uniquely 
considered. 
On the base of this research experience on COPD a new research protocol is 
actually been considering, aimed at the investigation of COPD heterogeneity 
that remains, despite the enormous progresses made in this field, an 
unsettled issue. 
Despite a universal definition of COPD, including all diseases characterized 
by poorly reversible airflow limitation [3], huge clinical, functional and 
radiological differences are described among individuals with COPD label 
and, more important, prognosis is diverse [4] and response to therapy may 
be different. COPD includes different specific phenotypes, chronic bronchitis 
(CB) pulmonary emphysema (PE) and, according to some authors, chronic 
asthma, when airways obstruction reversibility has disappeared. Major 
differences exist between asthma and COPD (CB/PE): clinical history, 
bronchial responsiveness, DLCO, biological markers and structural 
alterations of the lung usually permit to differentiate asthma from CB/PE, 
even for a similar degree of airway obstruction. A recent work of Fabbri et al. 
[5] highlights the importance of comparing asthma and chronic bronchitis 
patients of the same age class and with a comparable degree of airflow 
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obstruction. By using imaging (HRTC), functional (including salbutamol 
reversibility and methacholine responsiveness) and pathological techniques 
(exhaled NO, induced sputum, BAL, bronchial biopsy) the authors defined 
different phenotypes: patients with a history of asthma had more eosinophils 
in blood, sputum, BAL and airway mucosa, and a higher CD4/CD8 ratio of T 
cells infiltrating the airway mucosa. As expected, they also had less residual 
volume, higher DLCO, exhaled NO and reversibility to bronchodilator and 
steroids, and a lower HRTC-emphysema-score. ⋅ 
It is clear that a large variability exists also within the big group of patients 
with chronic bronchitis with or without emphysema, in symptoms (perception 
of dyspnoea, presence of cough and phlegm, etc.), time course, radiological 
aspects and systemic effects of the disease. Important functional differences 
are also observed in DLCO, residual volume and hyperinflation.  
In addition, beyond the old definition of COPD subtypes of “blue brothers” 
and “pink puffer” that correspond to important pathological and functional 
differences, today it has become common to differentiate patients by 
systemic effects of COPD, on the basis of exercise capacity, body mass 
index and the involvement of peripheral muscles. 
At the origin of such variability is probably the existence of different 
pathogenetic mechanisms, different factor risks and predisposing factors that 
are not easy to unravel. The literature on MIGET in COPD has put into 
evidence the existence of different patterns of VA/Q distributions and has 
showed the intent to find some correlation between functional data and 
structure even with some difficulties but the combination of MIGET with more 
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modern radiological and biological techniques could give us much more 
information [6-8] ⋅ 
The coexistence of chronic inflammation and oxidative stress alterations at 
level of small airways, of obstructive bronchiolitis and of parenchymal 
destruction in a variable proportion, makes COPD pathology extremely 
heterogeneous [9-11].  On this line, a new project of investigation has been 
planned on COPD heterogeneity (functional, biological and radiological 
features) that integrates the information deriving from HRCT and functional 
tests with ventilation - perfusion study (MIGET), biological measurements 
and markers of systemic involvement. 
The model of VA/Q study before and after the administration of inhaled 
salbutamol, a bronchodilator and vasoactive agent, could help to investigate 
the interplay of intra-pulmonary and extra-pulmonary factors modulating gas 
exchange in different pathogenetic conditions. 
The information deriving from the analysis of cell composition, inflammatory 
and oxidative stress markers in sputum and BAL (IL-8, TNF-a, NE, VEGF, 
MMP, NCA) and exhaled breath condensate (EBC) (8-isoprostane, MDA, 
LTB4, cys-LT) and from exhaled NO (bronchial and alveolar fractions) is 
fundamental to investigate the chronic inflammatory process causing airway 
remodelling, narrowing of small airways and loss of lung elastic recoil, and 
could have important therapeutical implications. 
Three classes of COPD patients could be selected, similar for age (55 - 65 
years) and airway obstruction (FEV1:  50 - 70% of predicted), by clinical 
history and radiological aspects: chronic asthma, chronic bronchitis with and 
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without emphysema. Possible targets of investigation are: the effects of 
inhaled salbutamol on gas exchange and ventilation/perfusion relationships; 
differences among the three classes of patients by the analysis of sputum, 
BAL, exhaled air and blood samples. The correlation among basal 
measurements of pulmonary function, gas exchange, inflammatory and 
oxidative stress markers can also be evaluated. The peripheral involvement 
could be evaluated through 6 min walking test and the evaluation of free fat 
mass (bio-electric impedance). ⋅ 
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